| Breast |
91% (n = 41 of 45) |
II |
42.9% of patients had 12 months of survival with CTCs (≥1). |
[114] |
| Breast |
11.2%(n = 51 of 455) |
III |
Not applicable. |
[115] |
| Breast |
39% (n = 148 of 378) |
II |
75% of trastuzumab-treated group showed CK19-negative CTCs. |
[116] |
| Colon |
37.5% (n = 180 of 480) |
III |
41% of CTC-positive (≥5) patients had 24 months survival. |
[117] |
| Lung |
44.4% (n = 8 of 18) |
II |
76.5% patients showed favorable CTC counts. |
[118] |
| Lung |
78% (n = 32 of 41) |
II |
18% of patients with ≥5 CTCs converted to favorable CTCs (<5). |
[119] |
| Ovary |
32.1% (n = 216 of 672) |
III |
CTC count was not correlated with survival. |
[120] |
| Prostate |
66% (n = 263 of 400) |
III |
Median progression-free survival times, 25.1 months (<3 CTCs) and 16.2 months (≥3 CTCs). |
[121] |
| Prostate |
71.5% (n = 88 of 123) |
I/II |
47% of patients with ≥2 positive and 28% of patients with <2 CTC biomarkers showed distant relapse. |
[122] |
| Prostate |
35.4% (n = 11 of 31) |
II |
Overall survival rate for 36 months was positive for 55% of patients with 1 positive and 42% of patients with 2-3 positive CTC biomarkers. |
[123] |
| Pancreas |
37.5% (n = 19 of 51) |
II |
Median overall survival times, 17.4 to 25.3 months (<2 CTCs) and 12.4 months (≥2 CTCs). |
[124] |
| Skin |
~13-17.5% (n = 44-56 of 320) |
III |
Unable to correlate with disease characteristics owing to low CTC counts. |
[125] |
| Skin |
86% (n = 214 of 269) |
III |
Increased progression-free survival with decreased CTC counts. |
[126] |
